CDTX Stock News & Analysis | Latest Updates

Cidara Therapeutics to Participate in September Investor Conferences

(NASDAQ:CDTX) SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences.

CDTX News

Cidara Therapeutics to Participate in September Investor Conferences

Cantor Fitzgerald Reiterates Overweight on Cidara Therapeuticsto Overweight

Needham Maintains Buy on Cidara Therapeutics, Raises Price Target to $36

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $47 Price Target

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $47 Price Target

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $47 Price Target

RBC Capital Maintains Outperform on Cidara Therapeutics, Raises Price Target to $35

Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target

Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $50

Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $35

JMP Securities Maintains Market Outperform on Cidara Therapeutics, Raises Price Target to $47

Cidara Therapeutics Q1 EPS $(1.66) Beats $(2.71) Estimate

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $46 Price Target

Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target

Cidara Therapeutics Announces Participation In WHO Panel On H5N1 Influenza Preparedness And Response, Discussing Pharmaceuticals As Preventive Tools On March 19, 2025

Cidara Therapeutics Announces 2 Presentations On CD388 In Influenza At ICAR 2025

Cidara Therapeutics Announced The Publication Of Preclinical Data Assessing CD388, The Company's Influenza Drug-fc Conjugate, In The Peer-reviewed Scientific Journal Nature Microbiology

Citizens Capital Markets Initiates Coverage On Cidara Therapeutics with Market Outperform Rating, Announces Price Target of $46

HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Raises Price Target to $35

Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target

Cidara Therapeutics Q4 2024 GAAP EPS $(5.37) Misses $(3.62) Estimate

Cidara Therapeutics Appoints Frank Karbe as CFO, Effective February 24, 2025

Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target

Cidara Therapeutics Announces Initiation Of Phase 2a Human Viral Challenge Trial To Evaluate CD388 For Universal Prevention Of Influenza